Sutro Biopharma, Inc. (STRO)

4,3500 +0,0700 (+1,64%) Alla chiusura: 04:00PM EDT

Sutro Biopharma, Inc.

111 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 881 6500
https://www.sutrobio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 302

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. William J. Newell J.D.	CEO & Director	1,06M	N/D	1958
Dr. Hans-Peter Gerber Ph.D.	Chief Scientific Officer	575,83k	N/D	1963
Ms. Jane Chung R.Ph.	President & COO	934,64k	N/D	1971
Dr. James R. Swartz DSc, Ph.D., Sc.D.	Founder	N/D	N/D	N/D
Mr. Edward C. Albini M.B.A	CFO & Secretary	596,4k	N/D	1958
Dr. Venkatesh Srinivasan Ph.d.	Chief Technical Operations Officer	N/D	N/D	1962
Mr. David Pauling J.D., M.A.	General Counsel	N/D	N/D	N/D
Ms. Linda A. Fitzpatrick	Chief People & Communications Officer	595,79k	N/D	1957
Dr. Nicki Vasquez Ph.D.	Chief Portfolio Strategy & Alliance Officer	N/D	N/D	1963
Ms. Regina Cheng	Vice President & Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Sutro Biopharma, Inc. al 1 maggio 2024 è 7. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.